Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Direxion Daily Semiconductor Bull 3X Shares (SOXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Direxion Daily Semiconductor Bull 3X Shares — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $282.6 (market cap $39.89B), while Direxion Daily Semiconductor Bull 3X Shares trades at $171.77. The key difference: Direxion Daily Semiconductor Bull 3X Shares is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | SOXL | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $491.22 | $300.77 |
52-Week Low | $278.09 | $23.99 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
SOXL trades at $192.26, down 0.1% on the day, with technical indicators signaling a bearish trend as moving averages and ADX point to selling pressure. Recent news highlights extreme volatility, including a 23% single-day drop on June 23, 2026, driven by sector-wide semiconductor sell-offs. The fund faces structural risks from its 3x leverage, which amplifies losses in choppy markets, as noted by Seeking Alpha on July 4, 2026.
The outlook remains high-risk due to leverage decay and semiconductor sector instability. Investment opportunities hinge on a broad AI-driven chip recovery, but risks include volatility decay, hedge fund selling (Goldman Sachs, July 6, 2026), and geopolitical tensions affecting oil markets (New York Post, July 8, 2026).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Direxion Daily Semiconductor Bull 3X Shares
SOXL is a leveraged ETF that seeks daily investment results corresponding to 300% of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bullish (long) position on the semiconductor sector. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXL →
